Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells

Chinese Medical Journal

Volumn 117, Issue 10, 2004, Pages 1558-1563

  Sun, Hua ^a   Yao, Kun ^a   Chen, Yun ^a   Zhou, Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell immunity; Dendritic cells; EB virus; Tumor

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS; FEASIBILITY STUDY; FEMALE; GENETIC TRANSFECTION; IN VIVO STUDY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; DENDRITIC CELLS; FEMALE; HERPESVIRUS 4, HUMAN; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VACCINATION; VIRAL MATRIX PROTEINS;

EID: 8844273313     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Banchereau J, Steinman RM. Dendrtic cells and the control of immunity. Nature 1998;392:245-252.
2. Morse MA, Lyerly HK. DNA and RNA modified dendritic cell vaccines. World J Surg 2002;26:819-825.
3. Sprinzl GM, Kacani L, Schrott-Fisher A, et al. Dendritic cell vaccines for cancer therapy. Cancer Treat Rev 2001;27: 247-255.
4. Baumforth KRN, Young LS, Flavell KJ, et al. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307-322.
5. Khanna R. Immune regulation in Epstein-Barr virus associated diseases. Microbiol Rev 1995;59:387-405.
6. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated disease. Ann Rev Microbiol 2000;54:19-48.
7. Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAP-1 and TAP-2) -independent endogenous processing of Epstein-Barr virus (EBV) latent membrane 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996;70:5357-5362.
8. Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 2002;62:171-17.
9. Steven NM, Annels NE, Kumar A, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T response. J Exp Med 1997;185:1605-1618.
10. Yao K, Peng GY, Ding CL, et al. Analysis of the specific cytotoxic T lymphocytes elicited by dendritic Cells transfected with the EBV latent membrane protein 2A recombinant adenovirus in vitro. Chin J Immunol. (in press)
11. Wang RF, Rosenberg R. Human tumor antigens for cancer vaccine development. Immunol Rev 1999;170:85-100.
12. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting and anti-tumor activity of dendritic cell vaccines. Cancer Res 1999;63:1860-1864.
13. Sharma S, Miller P, Stolina M, et al. T cell derived IL-10 promote lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020-5028.
14. Banchereau J, Schuler-Thurner B, Palucka AK, et al. Dendritic cells as vectors for gene therapy. Cell 2001;106: 271-274.
15. Schuler G, Schuler-Thurner B. Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-147.
16. Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol 1999;73:334-342.
17. + killer T cells. J Exp Med 2001;193:405-411.
18. Su Z, Peluso MV, Raffegerst SH, et al. The generation of LMP2A-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 2001;31:947-958.
19. Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 a cytokine profile. J Immunol 1998; 161:3033-3041.